# Accadis Hochschule Bad Homburg

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/accadis-hochschule-bad-homburg/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 47 |
| Citations | 9,874 |
| City | Bad Homburg |
| Country | DE |
| Description | Accadis Hochschule Bad Homburg is a research organisation in Bad Homburg, DE. OpenAlex records 1,362 works and 9,874 citations for it. 329 researchers list it as their most recent affiliation. |
| Homepage | http://international-students.accadis.com/ |
| OpenAlex ID | https://openalex.org/I4210097856 |
| Researchers | 329 |
| ROR ID | https://ror.org/015a98c38 |
| Type | education |
| Works | 1,362 |

## University papers

- [Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial](https://scholariq.org/papers/triple-hormone-receptor-agonist-retatrutide-for-obesity-a-phase-2-trial/)
- [Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis](https://scholariq.org/papers/tirzepatide-for-metabolic-dysfunction-associated-steatohepatitis-with-liver/)
- [LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept](https://scholariq.org/papers/ly3298176-a-novel-dual-gip-and-glp-1-receptor-agonist-for-the-treatment-of-type/)
- [Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-ly3298176-a-novel-dual-gip-and-glp-1-receptor-agonist-in/)
- [Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity](https://scholariq.org/papers/daily-oral-glp-1-receptor-agonist-orforglipron-for-adults-with-obesity/)
- [Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA](https://scholariq.org/papers/retatrutide-a-gip-glp-1-and-glucagon-receptor-agonist-for-people-with-type-2/)
- [Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes](https://scholariq.org/papers/effects-of-novel-dual-gip-and-glp-1-receptor-agonist-tirzepatide-on-biomarkers/)
- [Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes](https://scholariq.org/papers/dual-gip-and-glp-1-receptor-agonist-tirzepatide-improves-beta-cell-function-and/)
- [LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept](https://scholariq.org/papers/ly3437943-a-novel-triple-glucagon-gip-and-glp-1-receptor-agonist-for-glycemic/)
- [Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial](https://scholariq.org/papers/effects-of-tirzepatide-versus-insulin-glargine-on-kidney-outcomes-in-type-2/)
- [Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials](https://scholariq.org/papers/tirzepatide-associated-with-reduced-albuminuria-in-participants-with-type-2/)

## University researchers

- [Axel Haupt](https://scholariq.org/researchers/axel-haupt/)

## University top topics

- [Digital Innovation in Industries](https://scholariq.org/topics/digital-innovation-in-industries/)
- [Sociology and Education Studies](https://scholariq.org/topics/sociology-and-education-studies/)
- [Health and Medical Studies](https://scholariq.org/topics/health-and-medical-studies/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Medical Practices and Rehabilitation](https://scholariq.org/topics/medical-practices-and-rehabilitation/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Social and Demographic Issues in Germany](https://scholariq.org/topics/social-and-demographic-issues-in-germany/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.